No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
SPRY250117C5000
- 9.10
- 0.000.00%
15min DelayTrading Nov 15 10:10 ET
0.00High0.00Low
0.00Open9.10Pre Close0 Volume23 Open Interest5.00Strike Price0.00Turnover0.00%IV27.14%PremiumJan 17, 2025Expiry Date6.09Intrinsic Value100Multiplier25DDays to Expiry3.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.95Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
ARS Pharmaceuticals Says Express Scripts Has Added Neffy (Epinephrine Nasal Spray) To Its Commercial National Formularies
ARS Pharmaceuticals Announces Neffy (Epinephrine Nasal Spray) Is Available on Express Scripts Commercial National Formularies
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
ARS Pharmaceuticals Files For Approval Of Neffy In China, Japan And Australia
ARS Pharmaceuticals | 10-Q/A: Quarterly report (Amendment)
ARS Pharmaceuticals Announces That It Will Be Launching The NeffyinSchools Program In January 2025; The Program Will Provide Eligible Public And Private K-12 Schools In The U.S. The Opportunity To Receive Two Cartons Of Neffy 2mg For Use In Emergency...